Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study

Pharmacogenetics and Genomics

Volumn 22, Issue 5, 2012, Pages 367-372

  Irvin, Marguerite R ^a   Zhang, Qunyuan ^b   Kabagambe, Edmond K ^a   Perry, Rodney T ^a   Straka, Robert J ^c   Tiwari, Hemant K ^a   Borecki, Ingrid B ^b   Shimmin, Lawrence C ^d   Stuart, Colin ^d   Zhong, Yu ^d   Hixson, James E ^d   Arnett, Donna K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

clinical trials; DNA sequence analysis; lipids; peroxisome proliferator activated receptor

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ADULT; ARTICLE; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862779585     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328351a486     Document Type: Article

References (42)

1. Hodis HN, Mack WJ, Krauss RM, Alaupovic P. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: clinical aspects. Clin Cardiol 1999; 22 (6, Suppl):II15-II20. (Pubitemid 29265095)
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497.
3. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009; 169:572-578.
4. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011; 97:350-356.
5. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19: 2474-2486. (Pubitemid 29477850)
6. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009; 24:345-350.
7. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41: 945-952. (Pubitemid 30434326)
8. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010; 6:525-539.
9. Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002; 62: 1909-1944.
10. Brisson D, Methot J, Tremblay K, Tremblay M, Perron P, Gaudet D. Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenet Genomics 2010; 20:742-747.
11. Ordovas JM. Pharmacogenetics of lipid diseases. Hum Genomics 2004; 1:111-125.
12. Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, et al. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet 2008; 16:603-613. (Pubitemid 351594127)
13. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010; 5:e9763. Available at http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=2842298&tool= pmcentrez&rendertype=abstract.
14. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117:1537-1544.Available at http://www.ncbi.nlm.nih.gov/pubmed/18332269. (Pubitemid 351440642)
15. Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, et al. The - 256 T >C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem 2007; 53: 1144-1152. (Pubitemid 46867533)
16. Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Grundy SM, Knopp RH, et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986; 6: 670-678. Available at http://www.ncbi.nlm.nih.gov/pubmed/3535757. (Pubitemid 17190167)
17. Chew CH, Samian MR, Najimudin N, Tengku-Muhammad TS. Molecular characterisation of six alternatively spliced variants and a novel promoter in human peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 2003; 305:235-243. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 12745064. (Pubitemid 36555458)
18. Hixson JE, Shimmin LC, Montasser ME, Kim D-K, Zhong Y, Ibarguen H, et al. Common variants in the periostin gene influence development of atherosclerosis in young persons. Arterioscl Thromb Vasc Biol 2011; 31:1661-1667. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3116984&tool= pmcentrez&rendertype=abstract.
19. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Human Genet 2008; 83:311-321. Available at http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=2842185&tool=pmcentrez&rendertype=abstract.
20. Madsen BE, Browning SR. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet 2009; 5:e1000384. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2633048&tool= pmcentrez&rendertype=abstract.
21. Zhang Q, Irvin MR, Arnett DK, Province MA, Borecki I. A data-driven method for identifying rare variants with heterogeneous trait effects. Genet Epidemiol 2011; 35:679-685. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 21818776.
22. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. Available athttp://www.ncbi.nlm.nih.gov/pubmed/15297300. (Pubitemid 40202029)
23. Smigielski EM, Sirotkin K,Ward M, Sherry ST. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acid Res 2000; 28:352-355. vailable at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=102496&tool= pmcentrez&rendertype=abstract. (Pubitemid 30047805)
24. Pevsner J. Analysis of genomic DNA with the UCSC genome browser. Methods Mol Biol 2009; 537:277-301.
25. Myers RM, Stamatoyannopoulos J, Snyder M, Dunham I, Hardison RC, Bernstein BE, et al. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011; 9:e1001046. Available at http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3079585&tool=pmcentrez&rendertype=abstract.
26. Shin M-J, Kanaya AM, Krauss RM. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008; 198:313-319. Available at http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=2678963&tool=pmcentrez&rendertype=abstract. (Pubitemid 351707390)
27. Tai ES, Collins D, Robins SJ, O'Connor JJ, Bloomfield HE, Ordovas JM, et al.The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006; 187:153-160. Availableat http://www.ncbi.nlm. nih.gov/pubmed/16221474. (Pubitemid 43833359)
28. Tai ES, Corella D, Demissie S, Cupples LA, Coltell O, Schaefer EJ, et al. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutrit 2005; 135:397-403. Available at http://www.ncbi.nlm.nih.gov/pubmed/15735069. (Pubitemid 40365194)
29. Pritchard JK, Cox NJ. The allelic architecture of human disease genes: common disease-common variantyor not? Human Mol Genet 2002;11:2417-2423. Available at http://www.ncbi.nlm.nih.gov/pubmed/12351577. (Pubitemid 35174705)
30. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Human Genet 2001; 69:124-137. Available at http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=1226027&tool= pmcentrez&rendertype=abstract.
31. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461:747-753. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=2831613&tool=pmcentrez&rendertype=abstract.
32. Shi G, Rao DC. Optimum designs for next-generation sequencing to discover rare variants for common complex disease. Genet Epidemiol 2011;35:572-579. Available at http://www.ncbi.nlm.nih.gov/pubmed/21618604.
33. Brunham LR, Singaraja RR, Hayden MR. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Ann Rev Nutrit 2006; 26:105-129. Available at http://www.ncbi.nlm.nih.gov/pubmed/16704350.
34. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305:869-872. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 15297675. (Pubitemid 39038422)
35. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA 2006; 103:1810-1815. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1413637&tool=pmcentrez&rendertype=abstract. (Pubitemid 43228775)
36. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007; 39:513-516.Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2762948&tool= pmcentrez&rendertype=abstract. (Pubitemid 46514768)
37. Slatter TL, Jones GT,Williams MJA, van Rij AM, McCormick SPA. Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels. Clin Genet 2008; 73:179-184. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 18199144.
38. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39:311-318.Available at http://www.ncbi.nlm.nih.gov/pubmed/17277777. (Pubitemid 46328487)
39. Kimchi-Sarfaty C, Oh JM, Kim I-W, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-528. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 17185560. (Pubitemid 46175758)
40. Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin+ fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol2003; 92:794-797. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 14516878. (Pubitemid 37163572)
41. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome. Endocrine Metab Immune Disord Drug Targets 2010; 10:138-148. Available at http://www.ncbi.nlm.nih.gov/pubmed/20406163.
42. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32:493-498. Available at http://www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=2646035&tool=pmcentrez&rendertype=abstract.